<DOC>
	<DOCNO>NCT00005959</DOCNO>
	<brief_summary>RATIONALE : Monoclonal antibody rituximab locate cancer cell either kill deliver cancer-killing substance without harm normal cell . Drugs use chemotherapy use different way stop cancer cell divide stop grow die . Combining one chemotherapy drug rituximab may kill cancer cell . PURPOSE : Phase II trial study effectiveness rituximab plus combination chemotherapy treat patient intermediate-grade high-grade non-Hodgkin 's lymphoma .</brief_summary>
	<brief_title>Combination Chemotherapy Plus Rituximab Treating Patients With Intermediate-Grade High-Grade Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : I . Determine rate complete response partial response patient intermediate high grade non-Hodgkin 's lymphoma treat rituximab plus cyclophosphamide , doxorubicin , vincristine , prednisone ( CHOP ) . II . Determine toxicity regimen patient . III . Determine disease-free overall survival , time response , time disease progression patient treat regimen . OUTLINE : This multicenter study . Patients stratify accord number risk factor ( 0-2 v 3-5 ) . Risk factor include age ( great 60 v great 60 ) , tumor stage ( II v III IV ) , number extranodal sit ( 1 vs 1 ) , performance status ( 0-1 v 2-4 ) , serum LDH level ( great normal v great normal ) . Patients receive rituximab IV day 1 ; cyclophosphamide , doxorubicin , vincristine IV day 3 ; oral prednisone day 3-7 . Patients 60 also receive filgrastim ( G-CSF ) subcutaneously begin day 4 continue blood count recover ( patient receive G-CSF secondary prophylaxis ) . Treatment continue every 3 week 4 course absence disease progression unacceptable toxicity . Patients respond receive 2 course . Patients measurable disease 6 course receive rituximab IV weekly 4 consecutive week . This treatment continue every 6 month 4 course absence disease progression unacceptable toxicity . Patients measurable disease 6 course chemotherapy receive 2 course maximum 8 course CHOP , follow maintenance therapy rituximab ( describe ) . Patients follow every 6 month 2 year . PROJECTED ACCRUAL : Approximately 100 patient accrue study .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm intermediate high grade nonHodgkin 's lymphoma Stage II , III , IV disease Bcell lymphoid cell CD20 CD19 positive No mantle cell , lymphoblastic , peripheral Tcell nonHodgkin 's lymphoma Measurable evaluable disease No prior treatment lymphoma No known CNS metastases A new classification scheme adult nonHodgkin 's lymphoma adopt PDQ . The terminology `` indolent '' `` aggressive '' lymphoma replace former terminology `` low '' , `` intermediate '' , `` high '' grade lymphoma . However , protocol us former terminology . PATIENT CHARACTERISTICS : Age : 18 Performance status : Karnofsky 60100 % Life expectancy : At least 12 week Hematopoietic : Unless document bone marrow disease : Absolute neutrophil count least 1,500/mm3 Platelet count least 100,000/mm3 Hepatic : SGOT SGPT great 3 time upper limit normal Bilirubin great 1.5 mg/dL Renal : Creatinine great 2.0 mg/dL Cardiovascular : No history severe heart disease , cardiomyopathy , congestive heart failure LVEF normal MUGA echocardiogram Other : Not pregnant nursing Fertile patient must use effective contraception No active infection define : Clinical syndrome consistent viral bacterial infection ( e.g. , influenza , upper respiratory infection , urinary tract infection ) OR Fever clinical site infection identify OR Microbiologically documented infection , include , limited , bacteremia septicemia No known HIV positivity No known sensitivity E. coli derivative ( e.g. , asparaginase , human insulin , human growth hormone , interferon alfa2b ) No prior malignancy within past 5 year except surgically cure basal squamous cell skin cancer carcinoma situ cervix No psychiatric , addictive , disorder may preclude study PRIOR CONCURRENT THERAPY : Biologic therapy : See Disease Characteristics No concurrent biologic therapy except epoetin alfa No white blood cell transfusion Chemotherapy : See Disease Characteristics No concurrent chemotherapy Endocrine therapy : Not specify Radiotherapy : See Disease Characteristics No concurrent radiotherapy Surgery : At least 2 week since prior major surgery Other : No concurrent investigational therapy No prophylactic antibiotic</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2002</verification_date>
	<keyword>stage III grade 3 follicular lymphoma</keyword>
	<keyword>stage III adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage III adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage III adult diffuse large cell lymphoma</keyword>
	<keyword>stage III adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage III adult Burkitt lymphoma</keyword>
	<keyword>stage IV grade 3 follicular lymphoma</keyword>
	<keyword>stage IV adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage IV adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage IV adult diffuse large cell lymphoma</keyword>
	<keyword>stage IV adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage IV adult Burkitt lymphoma</keyword>
	<keyword>contiguous stage II grade 3 follicular lymphoma</keyword>
	<keyword>contiguous stage II adult diffuse small cleave cell lymphoma</keyword>
	<keyword>contiguous stage II adult diffuse mixed cell lymphoma</keyword>
	<keyword>contiguous stage II adult immunoblastic large cell lymphoma</keyword>
	<keyword>contiguous stage II adult diffuse large cell lymphoma</keyword>
	<keyword>contiguous stage II adult Burkitt lymphoma</keyword>
	<keyword>noncontiguous stage II grade 3 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II adult diffuse small cleave cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult diffuse mixed cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult immunoblastic large cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult diffuse large cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult Burkitt lymphoma</keyword>
</DOC>